ArticleCase reports in urology2026
Port-Site Seeding of Urothelial Carcinoma After Robotic-Assisted Radical Prostatectomy Accompanied With Elevated Serum Levels of Carbohydrate Antigen 19-9: A Case Report.
Article in Case reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma (UC) of the bladder has a high recurrence rate. Non-muscle-invasive bladder cancer (NMIBC) requires careful follow-up after transurethral resection (TUR). Some cases of extravesical recurrence of UC have been reported following radical cystectomy or nephroureterectomy; however, few such cases following robot-assisted radical prostatectomy (RARP) are known. A 77-year-old man presented to our hospital with high serum prostate-specific antigen (PSA) levels and atypical urothelial cells. Prostate biopsy and photodynamic diagnosis (PDD)-TURBT were performed. Pathological diagnoses were adenocarcinoma (Gleason score 3 + 4) of the prostate and UC (high grade, pT1 + Tis) of the bladder. Intravesical Bacillus Calmette-Guerin (BCG) was administered. One year after BCG therapy, examinations showed no evidence of UC recurrence; RARP was performed in another hospital on his will. Four months following RARP, elevated serum carbohydrate antigen 19-9 (CA19-9), palpable port-site subcutaneous indurations, and intraperitoneal nodules were detected by blood test and positron emission tomography/computed tomography (PET/CT). The subcutaneous indurations were pathologically diagnosed as UC. Platinum-based chemotherapy decreased the level of serum CA19-9. Cancer progression with the elevation of serum CA19-9 was observed during subsequent avelumab therapy, and enfortumab vedotin therapy was initiated. The patient died from cancer progression 30 months after extravesical recurrence of UC. RARP for patients with a past history of bladder tumor presents a risk of dissemination of UC due to urine leakage. Thorough examination for UC before RARP is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.